Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation
Abstract Epirubicin (EPI) is one of the potent breast cancer (BC) chemotherapeutic agents, but its adverse effects limit its efficacy. Herein, EPI was selected to be loaded in liposomal carrier, which has been targeted by a monoclonal antibody, Herceptin. The preparation process of liposomes was a m...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | IET Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1049/nbt2.12012 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546737868242944 |
|---|---|
| author | Farnaz Khaleseh Abbas Hemmati Azandaryani Fatemeh Fathian Kolahkaj Mozafar Khazaei Katayoun Derakhshandeh |
| author_facet | Farnaz Khaleseh Abbas Hemmati Azandaryani Fatemeh Fathian Kolahkaj Mozafar Khazaei Katayoun Derakhshandeh |
| author_sort | Farnaz Khaleseh |
| collection | DOAJ |
| description | Abstract Epirubicin (EPI) is one of the potent breast cancer (BC) chemotherapeutic agents, but its adverse effects limit its efficacy. Herein, EPI was selected to be loaded in liposomal carrier, which has been targeted by a monoclonal antibody, Herceptin. The preparation process of liposomes was a modified ethanol injection method followed by Herceptin conjugation. The in vitro cell toxicity and cellular uptake of optimum formulation against HER2+ and HER2− cancer cell lines were evaluated. The results showed that the drug loading (DL%) and encapsulation efficiency (EE%) of liposome preparation method yielded 30.62% ± 0.49% and 62.39% ± 8.75%, respectively. The average size of naked liposomes (EPI‐Lipo) and immunoliposomes (EPI‐Lipo‐mAb) was 234 ± 9.86 and 257.26 ± 6.25 nm, with a relatively monodisperse distribution, which was confirmed by SEM micrographs. The release kinetic followed Higuchi model for both naked and immunoliposomes. In vitro cytotoxicity study on three different BC cell lines including BT‐20, MDA‐MB‐453 and MCF‐7 demonstrated higher toxicity of EPI in the Herceptin conjugated form (EPI‐Lipo‐mAb) in comparison with the free EPI and EPI‐Lipo in HER2 overexpressing cell line. In addition, the cellular uptake study showed a higher uptake of immunoliposomes by MCF‐7 cells in comparison with naked liposomes. In conclusion, these data show that the targeted delivery of EPI to breast cancer cells can be achieved by EPI‐Lipo‐mAb in vitro, and this strategy could be used for breast cancer therapy with further studies. |
| format | Article |
| id | doaj-art-72d4dbb02c0f45498952f2fa3abd5706 |
| institution | Kabale University |
| issn | 1751-8741 1751-875X |
| language | English |
| publishDate | 2021-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | IET Nanobiotechnology |
| spelling | doaj-art-72d4dbb02c0f45498952f2fa3abd57062025-02-03T06:47:18ZengWileyIET Nanobiotechnology1751-87411751-875X2021-05-0115325726510.1049/nbt2.12012Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulationFarnaz Khaleseh0Abbas Hemmati Azandaryani1Fatemeh Fathian Kolahkaj2Mozafar Khazaei3Katayoun Derakhshandeh4Nano Drug Delivery Research Center Kermanshah University of Medical Sciences Kermanshah IranNano Drug Delivery Research Center Kermanshah University of Medical Sciences Kermanshah IranNano Drug Delivery Research Center Kermanshah University of Medical Sciences Kermanshah IranFertility and Infertility Research Center Kermanshah University of Medical Sciences Kermanshah IranDepartment of Pharmaceutics School of Pharmacy Hamadan University of Medical Sciences Hamadan IranAbstract Epirubicin (EPI) is one of the potent breast cancer (BC) chemotherapeutic agents, but its adverse effects limit its efficacy. Herein, EPI was selected to be loaded in liposomal carrier, which has been targeted by a monoclonal antibody, Herceptin. The preparation process of liposomes was a modified ethanol injection method followed by Herceptin conjugation. The in vitro cell toxicity and cellular uptake of optimum formulation against HER2+ and HER2− cancer cell lines were evaluated. The results showed that the drug loading (DL%) and encapsulation efficiency (EE%) of liposome preparation method yielded 30.62% ± 0.49% and 62.39% ± 8.75%, respectively. The average size of naked liposomes (EPI‐Lipo) and immunoliposomes (EPI‐Lipo‐mAb) was 234 ± 9.86 and 257.26 ± 6.25 nm, with a relatively monodisperse distribution, which was confirmed by SEM micrographs. The release kinetic followed Higuchi model for both naked and immunoliposomes. In vitro cytotoxicity study on three different BC cell lines including BT‐20, MDA‐MB‐453 and MCF‐7 demonstrated higher toxicity of EPI in the Herceptin conjugated form (EPI‐Lipo‐mAb) in comparison with the free EPI and EPI‐Lipo in HER2 overexpressing cell line. In addition, the cellular uptake study showed a higher uptake of immunoliposomes by MCF‐7 cells in comparison with naked liposomes. In conclusion, these data show that the targeted delivery of EPI to breast cancer cells can be achieved by EPI‐Lipo‐mAb in vitro, and this strategy could be used for breast cancer therapy with further studies.https://doi.org/10.1049/nbt2.12012biomedical materialscancercellular biophysicsdrug delivery systemsdrugsencapsulation |
| spellingShingle | Farnaz Khaleseh Abbas Hemmati Azandaryani Fatemeh Fathian Kolahkaj Mozafar Khazaei Katayoun Derakhshandeh Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation IET Nanobiotechnology biomedical materials cancer cellular biophysics drug delivery systems drugs encapsulation |
| title | Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation |
| title_full | Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation |
| title_fullStr | Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation |
| title_full_unstemmed | Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation |
| title_short | Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation |
| title_sort | enhancement of in vitro antitumour activity of epirubicin in her2 breast cancer cells using immunoliposome formulation |
| topic | biomedical materials cancer cellular biophysics drug delivery systems drugs encapsulation |
| url | https://doi.org/10.1049/nbt2.12012 |
| work_keys_str_mv | AT farnazkhaleseh enhancementofinvitroantitumouractivityofepirubicininher2breastcancercellsusingimmunoliposomeformulation AT abbashemmatiazandaryani enhancementofinvitroantitumouractivityofepirubicininher2breastcancercellsusingimmunoliposomeformulation AT fatemehfathiankolahkaj enhancementofinvitroantitumouractivityofepirubicininher2breastcancercellsusingimmunoliposomeformulation AT mozafarkhazaei enhancementofinvitroantitumouractivityofepirubicininher2breastcancercellsusingimmunoliposomeformulation AT katayounderakhshandeh enhancementofinvitroantitumouractivityofepirubicininher2breastcancercellsusingimmunoliposomeformulation |